Rozanolixizumab is a humanized monoclonal antibody targeting the neonatal Fc receptor (FcRn). Rozanolixizumab was granted orphan drug designation for the treatment of myasthenia gravis (MG).
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.